Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation

Cancer treatments often require combinations of molecularly targeted agents to be effective. mTORi (rapamycin) and HDACi (MS-275/entinostat) inhibitors have been shown to be effective in limiting tumor growth, and here we define part of the cooperative action of this drug combination. More than 60 h...

全面介紹

Na minha lista:
書目詳細資料
發表在:Mol Cancer Ther
Main Authors: Simmons, John K., Michalowski, Aleksandra M., Gamache, Benjamin J., DuBois, Wendy, Patel, Jyoti, Zhang, Ke, Gary, Joy, Zhang, Shuling, Gaikwad, Snehal, Connors, Daniel, Watson, Nicholas, Leon, Elena, Chen, Jin-Qiu, Kuehl, W. Michael, Lee, Maxwell P., Zingone, Adriana, Landgren, Ola, Ordentlich, Peter, Huang, Jing, Mock, Beverly A.
格式: Artigo
語言:Inglês
出版: 2017
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5587368/
https://ncbi.nlm.nih.gov/pubmed/28522584
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-17-0171
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍